Targeted Genetics (NASDAQ: [[ticker:TGEN]]), the Seattle-based gene therapy company struggling to avoid bankruptcy, said today that it has terminated a lease on a manufacturing facility in Bothell, WA. The company agreed to pay a $500,000 fee to terminate the lease on the facility, which will allow Targeted to avoid $12 million in lease payments through 2015. Targeted only has enough resources on hand to operate into August, and needs to strike one or more cash-generating transactions to stay alive, the company said.
Author: Luke Timmerman
Luke is an award-winning journalist specializing in life sciences. He has served as national biotechnology editor for Xconomy and national biotechnology reporter for Bloomberg News. Luke got started covering life sciences at The Seattle Times, where he was the lead reporter on an investigation of doctors who leaked confidential information about clinical trials to investors. The story won the Scripps Howard National Journalism Award and several other national prizes. Luke holds a bachelor’s degree in journalism from the University of Wisconsin-Madison, and during the 2005-2006 academic year, he was a Knight Science Journalism Fellow at MIT.
View all posts by Luke Timmerman
